Sanofi Posts More Positive Olipudase Alfa Data As Approval Decisions Loom
First Potential Therapy For Rare Lysosomal Storage Disease
Ahead of a PDUFA date of 3 July, Sanofi has added to the body of clinical evidence supporting olipudase alfa as a treatment for acid sphingomyelinase deficiency (ASMD), a rare, progressive and potentially life-threatening disease with no approved therapies.
